by Robert Bazell
|
| List Price: | $15.00 |
| Amazon Price: | $13.50 & eligible for FREE Super Saver Shipping on orders over $25. |
| You Save: | $1.50 (10%) |
| Average Rating: |  |
| Lowest New Price: | $8.55 |
| Availablitiy: | Usually ships in 24 hours |
|
 |
|
Product Description
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.
Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers.
Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.
From the Hardcover edition.
Amazon.com Review
Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer reads like a novel at first. Oncologist Dennis Slamon has spent 13 years "obsessed with a molecule called Her-2," which he believed "held the key to nothing less than curing breast cancer." The book chronicles the search to unlock the secrets of Her-2/neu, a protein that makes cancer cells grow quickly; the discovery of the Her-2/neu antibody, which resulted in tumors shrinking and, sometimes, remission of the cancer; and the development of the drug Herceptin. It is also the story of the women with breast cancer who participated in Herceptin's clinical trials, including Anne McNamara, who has been fighting tumor after tumor since 1978. The scientific and research-history sections are heavy and slow going, but Robert Bazell effectively juxtaposes the difficult scientific concepts and long research history of Her-2 with human drama. He keeps bringing the reader back to the threads of the personal stories we are following--especially the women with breast cancer and their determination to recapture their health. This is what makes Her-2 so compelling. --Joan Price
Customers who bought this item also bought
Average Customer Review:
1 of 1 people found the following review helpful:
 Well, written, for the most part, 2007-09-10
The book was well-written and interesting for the most part, but I think its conclusions misrepresent the contribution of Herceptin to the battle against breast cancer. Post-marketing studies have shown that Herceptin is not the wonder drug it was hoped to be. The book downplays the cardiac side-effects which are both more common and more serious than Bazell lets on. Nothing has changed in the battle against cancer. Despite the entry of this new weapon into the arsenal of oncologists, the quest to defeat cancer is still (to mix my metaphors) more like sticking boards in the sand to hold back the tide than building a sea wall.
0 of 0 people found the following review helpful:
Great Book, 2006-03-23
I read this book in just a few days. It prompted me to give myself a breast exam and low and behold I found a lump.
Turns out I had developed a cancerous tumor but caught it in the early stages. This book changed my life in sooo many ways
3 of 3 people found the following review helpful:
Wow, what a book!, 2003-01-13
I am a newly diagnosed young woman with breast cancer that over express her2/neu. I am considering taking Herceptin for an early stage cancer. I would not have this possible choice were it not for the wonderfuly minds and efforts of the people that created Herceptin. My thanks to Dr. Slamon and Dr. Ullrich! And really mostly, my thanks to the brave women who faced this horrible disease and enrolled in the trials. This book reads like a novel. I couldn't put it down and read it in 1 sitting. It's a thriller! If I had 1 small complaint it would be that it only very lightly touches on the possible side effect of heart damage especially when used in conjunction with Adriamycin, which weighs heavily on my mind. This is a great read for breast cancer patients and anyone who wants to read a great book.
3 of 3 people found the following review helpful:
A book that left me speechless, 2001-11-25
This book gave new light and explored old beliefs about breast cancer. I have never been so impressed by the intellect of such a powerful author as Robert Bazell. Every part of the Her-2 intereasted me and each page left me completely speechless. I would recommend this book everyone willing to explore the idea of an outstandingly facinating book.
10 of 10 people found the following review helpful:
Good to the Last Page, 2001-11-22
I had to read this book for my Biotechnology class and although I am close to failing it I found Her-2 to be pretty exciting book.
Her-2 by Bazell and King is about breast cancer, however, it reveals many other interesting things about the drug industry and how progress is made in the medical research field. There are different stories and view points and the authors have succesfully managed to combine all this into a book that both teaches and thrills us. I recommend this book to everyone who wants to learn more about breast cancer and about the insights of creating and bringing to the market a revolutionary drug - from selection of the trial patients to the President's office.
Price is accurate as of the date/time indicated. Prices and product availability are subject to change. Any price displayed on the Amazon website at the time of purchase will govern the sale of this product.
|
Store Categories
|